Immutep Ltd (ASX: IMM) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Immutep Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$436.37 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.45 billion
Earnings per share
-0.039
Dividend per share
N/A
Year To Date Return
18.48%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Immutep Ltd (ASX: IMM)
Latest News
Healthcare Shares
4 ASX healthcare stocks having a cracking run on Friday
Share Fallers
Why Cettire, Immutep, Paladin Energy, and Westgold shares are sinking today
Healthcare Shares
Guess which ASX healthcare stock is surging on big FDA news
Share Gainers
Why 29Metals, Immutep, Insignia, and Perenti shares are pushing higher today
Share Gainers
Why Immutep, Kingsgate, Netwealth, and Ora Banda shares are storming higher
Healthcare Shares
Why is this ASX healthcare stock rocketing 25% on Friday?
Share Gainers
Why Coronado Global, EML, Immutep, and Lendlease shares are storming higher
Healthcare Shares
'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside
Share Fallers
Why Abacus, Bannerman Energy, Immutep, and Pilbara Minerals shares are falling today
Share Fallers
Why APA Group, Immutep, NAB, and Immutep shares are sinking
Healthcare Shares
Why did this ASX healthcare stock just crash 47%?
Broker Notes
This speculative ASX stock could almost double in value
Frequently Asked Questions
-
No, Immutep does not pay dividends at this time.
-
Immutep Ltd listed on the ASX on 23 June 1988.
IMM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Immutep Ltd
Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.
IMM Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Oct 2024 | $0.30 | $0.00 | 0.00% | 2,624,384 | $0.30 | $0.31 | $0.30 |
| 22 Oct 2024 | $0.30 | $0.00 | 0.00% | 1,491,980 | $0.30 | $0.31 | $0.30 |
| 21 Oct 2024 | $0.30 | $0.00 | 0.00% | 6,459,362 | $0.30 | $0.31 | $0.30 |
| 18 Oct 2024 | $0.30 | $-0.01 | -3.28% | 3,161,207 | $0.31 | $0.31 | $0.30 |
| 17 Oct 2024 | $0.31 | $0.00 | 0.00% | 3,864,875 | $0.32 | $0.32 | $0.30 |
| 16 Oct 2024 | $0.31 | $-0.01 | -3.17% | 3,399,181 | $0.31 | $0.32 | $0.31 |
| 15 Oct 2024 | $0.32 | $-0.01 | -3.13% | 5,763,886 | $0.32 | $0.33 | $0.31 |
| 14 Oct 2024 | $0.32 | $0.00 | 0.00% | 2,621,828 | $0.32 | $0.33 | $0.32 |
| 11 Oct 2024 | $0.32 | $0.00 | 0.00% | 1,721,753 | $0.32 | $0.32 | $0.32 |
| 10 Oct 2024 | $0.32 | $0.01 | 3.17% | 2,332,010 | $0.31 | $0.33 | $0.31 |
| 09 Oct 2024 | $0.32 | $0.01 | 3.23% | 2,223,265 | $0.31 | $0.32 | $0.31 |
| 08 Oct 2024 | $0.31 | $-0.01 | -3.17% | 2,872,774 | $0.32 | $0.32 | $0.31 |
| 07 Oct 2024 | $0.32 | $0.00 | 0.00% | 972,313 | $0.32 | $0.32 | $0.31 |
| 04 Oct 2024 | $0.32 | $0.01 | 3.23% | 911,025 | $0.31 | $0.32 | $0.31 |
| 03 Oct 2024 | $0.31 | $-0.01 | -3.13% | 2,412,889 | $0.32 | $0.33 | $0.31 |
| 02 Oct 2024 | $0.32 | $-0.02 | -5.97% | 4,950,347 | $0.32 | $0.33 | $0.32 |
| 01 Oct 2024 | $0.34 | $0.01 | 3.08% | 1,787,515 | $0.33 | $0.34 | $0.32 |
| 30 Sep 2024 | $0.33 | $-0.02 | -5.88% | 2,181,474 | $0.33 | $0.34 | $0.33 |
| 27 Sep 2024 | $0.34 | $0.00 | 0.00% | 3,935,175 | $0.34 | $0.34 | $0.33 |
| 26 Sep 2024 | $0.35 | $0.00 | 0.00% | 2,725,488 | $0.34 | $0.35 | $0.34 |
| 25 Sep 2024 | $0.34 | $0.00 | 0.00% | 2,063,328 | $0.34 | $0.35 | $0.33 |
| 24 Sep 2024 | $0.34 | $0.00 | 0.00% | 6,009,224 | $0.35 | $0.35 | $0.34 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Oct 2024 | Pete Meyers | Issued | 388,889 | $130,277 |
Conversion of securities.
|
| 01 Oct 2024 | Pete Meyers | Exercise | 388,889 | $130,277 |
Conversion of securities. 777,778 Performance Rights
|
| 18 Sep 2024 | Marc Voigt | Buy | 29,500 | $10,030 |
On-market trade.
|
| 23 Nov 2023 | Lis (Elisabeth) Boyce | Issued | 589,955 | $174,036 |
Director remuneration. 589,955 Director Performance
Rights |
| 23 Nov 2023 | Russell Howard | Issued | 178,356 | $52,615 |
Director remuneration. 404,770 Director Performance Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Russell J Howard | Non-Executive ChairmanNon-Executive Director | May 2013 |
Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc.
|
| Mr Pete A Meyers | Non-Executive Deputy ChairmanNon-Executive Director | Feb 2014 |
Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC.
|
| Mr Marc Voigt | Chief Financial OfficerChief Executive OfficerExecutive Director | May 2012 |
Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments.
|
| Professor Frederic Triebel | Executive Director | Sep 2022 |
Professor Triebel founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Company's acquisition of Immutep S.A in December 2014. While working at IGR as an oncologist, he was also a Professor in Immunology at Paris University and a Director of an INSERM Unit from 1991 to 1996.
|
| Ms Lis (Elisabeth) Boyce | Non-Executive Director | Apr 2023 |
Ms Boyce is corporate lawyer. She is currently a partner at Piper Alderman and was previously a partner at Dentons, having been at DibbsBarker for nearly 30 years. She has involvement in the Life Sciences and Healthcare sectors and is currently deputy chair of AusBiotechs AusMedtech Advisory Group and a member of AusBiotechs NSW Leadership Committee.
|
| Ms Deanne Miller | Chief Operating OfficerCompany SecretaryGeneral Counsel |
-
|
|
| Ms Indira Naidu | Joint Company Secretary | Jan 2021 |
-
|
| Deanne Miller | Chief Operating OfficerCompany SecretaryGeneral Counsel |
-
|
|
| Indira Naidu | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 386,571,289 | 32.56% |
| J P Morgan Nominees Australia Pty Limited | 165,050,307 | 13.90% |
| Citicorp Nominees Pty Limited | 81,121,672 | 6.83% |
| Tripp Investments Pty Ltd <Tripp Investment A/C> | 70,936,692 | 5.97% |
| Tekkorp Holdings Llc | 39,284,648 | 3.31% |
| National Nominees Limited | 11,243,351 | 0.95% |
| Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 11,191,695 | 0.94% |
| Edinburgh Park Stud Pty Ltd | 8,653,764 | 0.73% |
| Todd Cameron Buckingham | 7,692,440 | 0.65% |
| Rbw Nominees Pty Ltd <Rbw Discretionary A/C> | 7,584,327 | 0.64% |
| Mr David Mark Rocci | 6,862,905 | 0.58% |
| Bridgetrack Investments Pty Ltd | 6,484,177 | 0.55% |
| Revilo Corporate Pty Ltd <Revilo Corporate A/C> | 6,053,816 | 0.51% |
| Tjct Pty Limited <Buckingham Super Fund A/C> | 4,978,772 | 0.42% |
| P G Binet (No 5) Pty Ltd | 4,799,700 | 0.40% |
| J & M Hunter Investments Pty Ltd <J & M Hunter Investment A/C> | 4,114,620 | 0.35% |
| Ada Services (Nsw) Pty Ltd <Ada Services Super Fund A/C> | 3,800,000 | 0.32% |
| Hawksburn Capital Pte Ltd <Methuselah Strategic Fnd A/C> | 3,267,305 | 0.28% |
| Christopher Robert Begg | 3,074,592 | 0.26% |
| Mr Karl Alexander Begg | 2,774,395 | 0.23% |
